Potential beneficial effects of butyrate in intestinal and extraintestinal diseases.
By R. B. Canani, M. Costanzo, L. Leone, Monica Pedata, R. Meli, A. Calignano. World Journal of Gastroenterology, 2011
1,273 citations recorded by the source corpus.
The multiple beneficial effects on human health of the short-chain fatty acid butyrate, synthesized from non-absorbed carbohydrate by colonic microbiota, are well documented. At the intestinal level, butyrate plays a regulatory role on the transepithelial fluid transport, ameliorates mucosal inflammation and oxidative status, reinforces the epithelial defense barrier, and modulates visceral sensitivity and intestinal motility. In addition, a growing number of studies have stressed the role of butyrate in the prevention and inhibition of colorectal cancer. At the extraintestinal level, butyrate exerts potentially useful effects on many conditions, including hemoglobinopathies, genetic metabolic diseases, hypercholesterolemia, insulin resistance, and ischemic stroke. The mechanisms of action of butyrate are different; many of these are related to its potent regulatory effects on gene expression. These data suggest a wide spectrum of positive effects exerted by butyrate, with a high potential for a therapeutic use in human medicine.
View Paper: https://www.semanticscholar.org/paper/9d6ec7ddef84f5ee5b07e20b0256a819c641d330
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Ting He
- Guolong Zhang
- Xi Ma
- Niousha Ahmari
- Defa Li
- Jessica Marulanda Carvajal
- M. Raizada
- Y. Qi
Citations in the corpus
- The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? (2016, unknown): “Yet, the molecular mechanisms mediating these functions may differ, ranging from metabolic effects to receptor signalling and enzymatic inhibition, and are not completely understood (Canani et al., 2011).”
- Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health (2016, unknown): “Butyrate promotes colon motility, reduces inflammation, increases visceral irrigation, induces apoptosis, and inhibits tumor cell progression (Zhang et al., 2010; Canani et al., 2011; Leonel and Alvarez-Leite, 2012; Keku et al., 2015), all of these properties being beneficial in CRC prevention.”
- Butyrate: A Double-Edged Sword for Health? (2018, background): “For example, butyrate is capable of upregulating the expression of mucin 2 (MUC2) (74), which is the most prominent mucin on the intestinal mucosal surface and can reinforce the mucous layer, leading to the enhanced protection against luminal pathogens (1, 74).”
- Colonic bacterial composition in Parkinson's disease (2015, unknown): “Short-chain fatty acids (SCFAs), especially butyrate-producing bacteria at the intestinal level, play a major regulatory role in the intestinal ecosystem to maintain gastrointestinal function and body health.(29-32) Please refer to the K E S H A V A R Z I A N E T A L”
- GUT MICROBIOTA DYSBIOSIS IS LINKED TO HYPERTENSION (2015, background): “and suppression of colorectal cancer to name a few effects in the intestine.(45) Systematically, butyrate has been shown to prevent immune cell infiltration(46) and improve renal function following ischemic damage.”
- Human Gut Microbiota and Gastrointestinal Cancer (2018, unknown): “Conversely, butyric acid (BA), an important short-chain fatty acid (SCFA) that is generated from fermentable fibers in diets by colonic bacteria, has been shown to be anti-tumorigenic [81].”
- Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics (2017, unknown): “Much has been reported about the benefits of butyrate in the gut and beyond 54 , leading to the potential of known butyrate producers such as Faecalibacterium prausnitzii , Eubacterium rectale or Roseburia spp. as possible pro biotics and, therefore, new prebiotic targets.”